2-methoxymethoxy-1-iodoethane | 121934-15-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methoxymethoxy-1-iodoethane
• 英文别名: 1-iodo-2-methoxymethoxy-ethane；1-Iodo-2-methoxymethoxyethane；1-iodo-2-(methoxymethoxy)ethane
• CAS: 121934-15-4
• 化学式: C₄H₉IO₂
• 分子量: 216.019
• InChiKey: QVWHVTFBSVIBJM-UHFFFAOYSA-N

物化性质

• 沸点：
  164.4±20.0 °C(Predicted)
• 密度：
  1.712±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  7
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methoxymethoxy-1-iodoethane 、 (1R,2S,4aR,8aS)-2,4a-Dimethyl-5-methylene-decahydro-naphthalene-1-carbonitrile 在 potassium diisopropylamide 作用下， 生成 (1S,2S,4aR,8aR)-1-(2-Methoxymethoxy-ethyl)-2,4a-dimethyl-5-methylene-decahydro-naphthalene-1-carbonitrile
  参考文献：
  名称：

  Total synthesis of cis-clerodane diterpenoids: (–)-agelasine A and (+)-(3R,4S,5R,8S,9R,10S)-3,4-epoxyclerod-13-en-15,16-olide

  摘要：

  The preparation of the enantiomerically homogeneous bicyclic iodide 26 and its use as a key intermediate for the total syntheses of the cis-clerodane diterpenoids (-)-agelasine A 5 and (+)-(3R,4S,5R,8S,9R,10S)-3,4-epoxyclerod-13-en-15,16-olide 6 are described.

  DOI：

  10.1039/p19950000963
• 作为产物：
  描述：

  1-氯-2-(甲氧基甲氧基)乙烷 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 30.0h， 以50%的产率得到2-methoxymethoxy-1-iodoethane
  参考文献：
  名称：

  对-环戊烷二萜类化合物（±）-异芳基二醇和（±）-异芳基二醇二乙酸酯的全合成

  摘要：

  通过九步反应序列，将先前描述的双环[4.4.0]癸碳腈[（4）和（5）]混合物转化为（±）-异芳基二醇（3），可轻松将其转化为相应的双乙酸盐（2）。

  DOI：

  10.1039/c39880001245

文献信息

• 一种制备(3R ,3aS,6aR)六氢呋喃并[2,3-b] 呋喃-3-醇的方法
  申请人：青岛科技大学

  公开号：CN106928248B

  公开（公告）日：2019-01-04

  本发明属于化学合成领域，公开了一种制备地瑞那韦中间体(3R,3aS,6aR)六氢呋喃并[2,3‑b]呋喃‑3‑醇的方法。以(R)‑3‑羟基‑4‑羟基丁醛衍生物(I)为原料，在催化剂作用下立体选择性地与乙二醇衍生物反应得到中间体(II)，所得中间体(II)脱除保护基后在酸性条件下环化得(3R,3aS,6aR)六氢呋喃并[2,3‑b]呋喃‑3‑醇。该制备方法原料廉价易得，反应立体选择性高，操作简单，路线短，成本低，适合地瑞那韦的工业化生产。
• Simple design for the construction of complex gibberellin framework—Stereoselective synthesis of a possible key intermediate to GA12 via Pd2+-promoted cycloalkenylation reaction
  作者：Masahiro Toyota、Toshihiro Wada、Youichi Nishikawa、Keiko Yanai、Keiichiro Fukumoto、Chizuko Kabuto

  DOI：10.1016/0040-4020(95)00341-5

  日期：1995.6

  A successful design for the construction of C20 gibberellin framework has been described. The key features of the synthesis are as follows: (a) Pd2+-promoted cycloalkenylation reaction (6→5) and (b) intramolecular Diels-Alder reaction (4→3).

  已经描述了用于构建C 20赤霉素框架的成功设计。合成的关键特征如下：（a）Pd 2+促进的环烯基化反应（6 → 5）和（b）分子内Diels-Alder反应（4 → 3）。
• “<i>Syn</i>-<i>Effect</i>” in the Isomerization of (<i>E</i>)-<i>α</i>-Fluorovinylic Sulfones to the Corresponding Allylic Sulfones under Basic Conditions
  作者：Tetsuya Nakamura、Samar Kumar Guha、Yoshihiro Ohta、Daisuke Abe、Yutaka Ukaji、Katsuhiko Inomata

  DOI：10.1246/bcsj.75.2031

  日期：2002.9

  Toward the elucidation of the origin of the “syn-effect,” the stereochemistry of the isomerization of (E)-α-fluorovinylic sulfones to the corresponding allylic sulfones under mild basic conditions was investigated. The ratio of (Z)-isomers of the resulting allylic sulfones decreased in the following order for the γ-substituents of the starting vinylic sulfones: F- > EtO- > CH3- > BnS- > CH3CH2- > (CH3)2CH- > (CH3)3C-, C6H5-. The fluorine atom showed the highest “syn-effect,” which is herein defined as an effect that stabilizes the syn-conformation in the transition state against a steric or nonbonded repulsion; the rest of the series was in accord with previous results found in the conversion of α-unsubstituted (E)-vinylic sulfones to the corresponding allylic sulfones under similar conditions. These results were rationalized based on the σ→π* interaction.

  为了阐明“同分异构效应”的起源，研究人员研究了在温和碱性条件下（E）-α-氟乙烯基砜与相应的烯丙基砜的异构化立体化学。对于起始乙烯基砜的γ-取代基，所得烯丙基砜的（Z）-异构体的比例按以下顺序递减：F- > EtO- > CH3- > BnS- > CH2- > ( )2CH- > ( )3C-, C6H5-。氟原子表现出最强的“同分异构效应”，该效应在此定义为在过渡态下稳定同分异构体构象，使其免受空间位阻或非键排斥力的影响；该系列其余部分与之前在类似条件下将α-未取代（E）-乙烯基砜转化为相应的烯丙基砜的结果一致。这些结果基于σ→π*相互作用得到了合理的解释。
• Amine compounds and use thereof
  申请人：Yamazaki Toru

  公开号：US20050165063A1

  公开（公告）日：2005-07-28

  It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

  本发明旨在提供新型胺化合物，其对感染HIV病毒、风湿病和癌症转移等疾病具有疗效。即以下通式（1）所代表的胺化合物：在典型情况下，A1和A2分别代表可选择取代的单环或多环芳香杂环；W代表环状C3-10烷基，可选择取代的单环或多环芳香杂环，单环或多环芳香环或部分饱和多环芳香环；X代表O，CH2，C（═O）或NR11；D是以下通式（4）或（6）所代表的基团。在公式（6）中，Q代表单键，S，O或NR12；Y代表以下通式（7）所代表的基团。z代表可选择取代的单环或多环芳香环。在公式（6）中，B代表NR25R26。在上述公式中，R1至R26每个代表氢，烷基，烯基或炔基。
• Amine compound and use thereof
  申请人：Yamazaki Toru

  公开号：US20070208033A1

  公开（公告）日：2007-09-06

  It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

  本发明旨在提供新型胺类化合物，其对诸如感染HIV病毒、风湿病和癌症转移等疾病具有疗效。具体来说，本发明提供以下通式（1）所表示的胺类化合物：其中，在典型情况下，A1和A2分别表示可选取代的单环或多环芳香杂环；W表示环状C3-10烷基，可选取代的单环或多环芳香杂环，单环或多环芳香环或部分饱和多环芳香环；X表示O、CH2、C（═O）或NR11；D是由以下通式（4）或（6）表示的基团。在公式（6）中，Q表示单键，S、O或NR12；Y是由以下通式（7）表示的基团。z表示可选取代的单环或多环芳香环。在公式（6）中，B表示NR25R26。在上述公式中，R1至R26分别表示氢、烷基、烯基或炔基。